These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Attitudes of CCOP physicians toward clinical trials and protocol accrual. Vinciguerra V; Moore T Prog Clin Biol Res; 1990; 339():401-7. PubMed ID: 2392432 [No Abstract] [Full Text] [Related]
7. Population attitudes toward oncology clinical trials. Valentino J; Andrykowski MA; Wood TA J Ky Med Assoc; 1999 Mar; 97(3):111-7. PubMed ID: 10189772 [TBL] [Abstract][Full Text] [Related]
8. Uncertainty in assessing value of oncology treatments. Mullins CD; Montgomery R; Tunis S Oncologist; 2010; 15 Suppl 1():58-64. PubMed ID: 20237219 [TBL] [Abstract][Full Text] [Related]
9. Designing and funding clinical trials of novel therapies. Antman K; Lagakos S; Drazen J N Engl J Med; 2001 Mar; 344(10):762-3. PubMed ID: 11236782 [No Abstract] [Full Text] [Related]
10. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. Duff JM; Leather H; Walden EO; LaPlant KD; George TJ J Natl Cancer Inst; 2010 May; 102(10):702-5. PubMed ID: 20410466 [TBL] [Abstract][Full Text] [Related]
11. The relevance of practice misalignments to trials in transfusion medicine. Deans KJ; Minneci PC; Klein HG; Natanson C Vox Sang; 2010 Jul; 99(1):16-23. PubMed ID: 20345517 [TBL] [Abstract][Full Text] [Related]
12. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. Newman LA; Hurd T; Leitch M; Kuerer HM; Diehl K; Lucci A; Giuliano A; Hunt KK; Putnam W; Wells SA J Am Coll Surg; 2004 Oct; 199(4):644-51. PubMed ID: 15454152 [TBL] [Abstract][Full Text] [Related]
13. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. National Institutes of Health Consensus Development Panel J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285 [TBL] [Abstract][Full Text] [Related]
14. Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer. Begg CB Bull Cancer; 1987; 74(2):197-203. PubMed ID: 3607303 [TBL] [Abstract][Full Text] [Related]
15. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112 [TBL] [Abstract][Full Text] [Related]
16. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Prasad KN Integr Cancer Ther; 2004 Dec; 3(4):310-22. PubMed ID: 15523102 [TBL] [Abstract][Full Text] [Related]
17. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. Kimmick GG; Peterson BL; Kornblith AB; Mandelblatt J; Johnson JL; Wheeler J; Heinze R; Cohen HJ; Muss HB J Clin Oncol; 2005 Apr; 23(10):2201-7. PubMed ID: 15800312 [TBL] [Abstract][Full Text] [Related]
18. Innovative use of topical metronidazole. Zip CM Dermatol Clin; 2010 Jul; 28(3):525-34. PubMed ID: 20510762 [TBL] [Abstract][Full Text] [Related]
19. Rethinking the randomized clinical trial: the 21st century application of Freireich's laws. [An interview with Emil J Freireich by H&O]. Freireich EJ Clin Adv Hematol Oncol; 2008 Nov; 6(11):801-4. PubMed ID: 19194362 [No Abstract] [Full Text] [Related]
20. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]